StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a research report released on Saturday. The brokerage issued a sell rating on the medical research company’s stock.
Organovo Price Performance
Organovo stock opened at $0.44 on Friday. The company has a market cap of $6.35 million, a PE ratio of -0.27 and a beta of 0.61. The company has a fifty day moving average price of $0.51 and a two-hundred day moving average price of $0.73. Organovo has a 12 month low of $0.43 and a 12 month high of $2.05.
Organovo (NASDAQ:ONVO – Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.15. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.03 million. Equities research analysts anticipate that Organovo will post -0.96 earnings per share for the current year.
Institutional Investors Weigh In On Organovo
About Organovo
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Featured Articles
- Five stocks we like better than Organovo
- Election Stocks: How Elections Affect the Stock Market
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- 10 Best Airline Stocks to Buy
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What Are Dividend Contenders? Investing in Dividend Contenders
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.